?Semaglutide (CAS 99291-20-0)?
?? ?ChemicalBook Product Introduction?

?? ?Product Overview?

?Semaglutide? (C???H???N??O??), a ?long-acting GLP-1 receptor agonist?, is a breakthrough peptide therapeutic with a molecular weight of ?4113.58 g/mol?. This ?white to off-white powder? (≥99% purity, HPLC validated) is designed for ?type 2 diabetes management? by enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner?12. Supplied in sealed aluminum foil bags, it is stable under ?dry, light-protected storage? for up to ?3 years??23.

?Google Keywords?: Semaglutide CAS 99291-20-0, GLP-1 Agonist API Supplier, High-Purity Diabetes Therapeutic, Pharmaceutical Raw Materials

? ?Key Advantages?

      ?? ?Ultra-High Purity?

• ?≥99% purity? (HPLC, MS validated) | Complies with ?EP/USP/CP? standards?13.
  ?? ?Long-Acting Efficacy?

• Sustained glycemic control with ?weekly dosing? | Reduces cardiovascular risks?23.
  ?? ?GMP-Certified Production?

• Manufactured in ?ISO 9001? and ?GMP-compliant facilities? | REACH and FDA-aligned protocols?13.

?? ?Application Fields?

• ?Diabetes Therapeutics?: Core ingredient in injectable/oral formulations for type 2 diabetes?13.

• ?Pharmaceutical R&D?: Key intermediate for GLP-1 analog drug development?12.

• ?Bulk API Supply?: Global distribution for diabetes drug manufacturing?34.

?? ?Quality Certifications?

• ?Testing Methods?: HPLC, NMR, mass spectrometry, microbial limits?12.

• ?Certifications?: ?GMP?, ?ISO 9001?, ?REACH?, and ?ICH stability guidelines??13.

?? ?Market Trends?

The ?global diabetes drug market? is projected to reach ?$85 billion by 2030? (CAGR 6.1%), driven by rising diabetes prevalence and demand for non-insulin therapies?15. Semaglutide dominates as a dual-action agent for glycemic control and weight loss, with Asia-Pacific leading API production?23.

?? ?Contact us? for COA, custom synthesis, and bulk pricing!